The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.

Hao LiChao LiangDonglin KuangGuohao HuangMengfan ZhangPengfei ChenQingzhu ZhengWenze XuJianzhuang RenXinwei HanXuhua Duan

Published in: Cancer biology & therapy (2023)

DEB-TACE displays attenuated hepatic fibrosis progression and noninferior tolerance compared to cTACE in treating intermediate- or advanced-stage HCC patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
radiofrequency ablation
patient reported outcomes